# From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers

> **NCT02863900** · NA · UNKNOWN · sponsor: **Institut Claudius Regaud** · enrollment: 350 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** cohort of BC of each subtypes

## Key facts

- **NCT ID:** NCT02863900
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2016-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02863900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02863900, "From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT02863900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*